Reslizumab intravenous (IV) vs placebo
Serious adverse events · people with asthma
Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.79 [0.56, 1.12]4 studies · 1656 participantsHigh